

1 **Category of paper: Original Article**

2 **Article title: Risk factors for bacterial infections in patients with moderate to severe COVID-19: A**  
3 **case control study**

4  
5 N. Nasir<sup>1</sup>, F. Rehman<sup>1</sup>, S.F. Omair<sup>1</sup>

6 <sup>1</sup>Dept. of Medicine, Aga Khan University, Karachi, Pakistan

7

8

9 **Corresponding Author**

10 Nosheen Nasir *FRCP (Edin), FCPS (IM)FCPS (ID), MSc*

11 Assistant Professor, Dept. of Medicine

12 Aga Khan University, Stadium Road, Karachi 74800, Pakistan

13 Email: [Nosheen.nasir@aku.edu](mailto:Nosheen.nasir@aku.edu)

14 Phone: +922134864574

Fax: +922134932095

15

16 **Running Title:** Bacterial Infections in patients with COVID-19

17 **Funding:** No funding was available for this study

18 None of the authors have any conflict of interest

19

20

21 **ABSTRACT**

22 **Objective**

23 Bacterial infections are known to complicate respiratory viral infections and are associated with  
24 adverse outcomes in COVID-19 patients. A case control study was conducted to determine risk  
25 factors for bacterial infections where cases were defined as moderate to severe/critical COVID-19  
26 patients with bacterial infection and those without were included as controls. Logistic regression  
27 analysis was performed.

28 **Results**

29 Out of a total of 50 cases and 50 controls, greater proportion of cases had severe or critical  
30 disease at presentation as compared to control i.e 80% vs 30% ( $p < 0.001$ ). Hospital acquired  
31 pneumonia (72%) and Gram negative organisms (82%) were predominant. Overall antibiotic  
32 utilization was 82% and was 64% in patients who had no evidence of bacterial infection. The  
33 median length of stay was significantly longer among cases compared to controls (12.5 versus 7.5  
34 days) ( $p = 0.001$ ). The overall mortality was 30%, with comparatively higher proportion of deaths  
35 among cases (42% versus 18%) ( $p = 0.009$ ). Severe or critical COVID-19 at presentation (AOR: 4.42  
36 times; 95% CI; 1.63-11.9) and use of steroids (AOR: 4.60; 95% CI 1.24-17.05) were independently  
37 associated with risk of bacterial infections. These findings have implications for antibiotic  
38 stewardship as antibiotics can be reserved for those at higher risk for bacterial superinfections.

39 **Key words**

40 Bacteria ; COVID-19; nosocomial infections; co-infection.

## 41 INTRODUCTION

42 COVID-19 pandemic has claimed more than 1,000,000 lives to date and its long term impact is yet  
43 to be determined. Respiratory viral infections have been well known to predispose patients to co-  
44 infections and these lead to increased disease severity and mortality as was observed in 1918  
45 influenza outbreak, where most mortalities were due to simultaneous bacterial infection.[1]  
46 Bacterial co-infection also led to poor outcome in 2009H1N1 influenza pandemic.[2]

47 The incidence of bacterial co-infection in COVID-19 ranges from 3-30% [3, 4]. Zhou and colleagues  
48 showed that in the current coronavirus disease 2019 (COVID-19) pandemic, 50% of patients who  
49 died, had secondary bacterial infections, while another study showed presence of both bacterial  
50 and fungal infection [5, 6]. Due to similar clinical phenotype and difficulties in identifying COVID-  
51 19 disease from atypical bacterial pneumonia or nosocomial pneumonia some guidelines advise  
52 empirical antibiotics [7]. In a study conducted at 38 hospitals in Michigan 56.6% patients received  
53 empirical antibiotics therapy[8].

54 Studies indicate that bacterial co-infection and secondary infection complicate COVID-19 though  
55 regional data is scarce[6]. Moreover risk factors for these infections need to be better elucidated.  
56 Antimicrobials are used empirically which may lead to antimicrobial resistance in the long term.  
57 Hence, it is imperative to conduct comparative studies to identify those COVID-19 patients who  
58 are candidates for empirical antibiotic therapy and curtail widespread injudicious use of  
59 antibiotics. The purpose of this study is to determine the risk factors of bacterial infections in  
60 patients and characterization of these infections along with the sensitivity patterns of isolated  
61 organisms in patients presenting with moderate to severe/critical COVID-19.

62 **MAIN TEXT**

63 **METHODS**

64 A case control study was conducted from February 2020 to June 2020 at a tertiary care center in  
65 Karachi, Pakistan. Cases were defined as patients who had PCR confirmed moderate to  
66 severe/critical COVID-19 as per WHO criteria for severity and had evidence of bacterial infection  
67 based on isolation of bacteria in any of the culture specimens collected during admission along  
68 with symptoms and signs consistent with infection. Controls were defined as patients who had  
69 PCR confirmed moderate to severe/critical COVID-19 as per WHO criteria for severity but who did  
70 not develop bacterial infection during admission.

71 All adult patients (age  $\geq 18$  years) hospitalized with moderate and severe/critical COVID-19 as per  
72 WHO definition for severity [9] at Aga Khan University Hospital, Karachi were assessed for  
73 presence of bacterial co-infection at admission as well as followed for secondary bacterial  
74 infection during hospitalization. Patients with signs and symptoms consistent with bacterial  
75 infection during hospitalization with COVID-19 at various sites such as urinary tract infection,  
76 hospital acquired pneumonia, ventilator associated pneumonia, central line associated blood-  
77 stream infection etc. as defined by CDC [10] and who were identified to have growth of significant  
78 bacteria in the respective appropriate culture specimens (e.g urine, tracheal aspirate, blood from  
79 central line etc) collected during admission were included whereas those patients who had  
80 evidence of bacterial infection on culture but did not have signs and symptoms consistent with  
81 infection at any site as defined by CDC [10] were considered to be colonized and excluded from  
82 study and patients with mono-microbial fungal infections were also excluded.

83 Patients who had any positive bacterial culture were identified from infection control records and  
84 were screened for eligibility criteria for cases. Controls were identified from medical records among  
85 all moderate to severe/critical COVID-19 admissions. A sample size of 50 cases was obtained. For  
86 each case patient, 1:1 control patient(s) was also obtained (50 controls). Main outcome variable was  
87 presence of bacterial infection defined as infection with clinically significant bacteria which is  
88 identified from a culture specimen among those with moderate or severe/critical COVID-19.  
89 Exposure variables included patient related factors such as age in years, gender, comorbidities, type  
90 of ward/unit to which patient was admitted, presence of invasive devices and immunosuppression  
91 received. We collected data on potential confounders including previous co-morbidities and severity of  
92 illness. Data was collected on structured proforma which was pretested for one week at the start of  
93 the study. Patients were further stratified as having community-onset infection if they had culture  
94 specimen positive within 72 hours of admission and hospital-onset infection if they were found to  
95 have a bacterial infection after 72 hours of hospitalization. Bacteriological identification was  
96 performed in College of American Pathologists (CAP) certified Clinical Microbiology laboratory at Aga  
97 Khan University by conventional methods. Antibiotic susceptibility of isolated bacteria was evaluated  
98 by the standard disc diffusion method in accordance with the Clinical & Laboratory Standards  
99 Institute (CLSI) recommendations.

#### 100 Statistical analysis

101 Frequencies with percentages were reported for categorical variables such as gender, type of  
102 infection by site, etc. according to case or control status. For continuous variables such as age,  
103 length of stay etc. median and interquartile range were reported by case and control status.  
104 Logistic regression analysis was performed to determine the association between risk factors and

105 bacterial infection in moderate and severe/critical COVID-19 patients and the results were  
106 reported as adjusted odds ratios with 95% confidence intervals. P-value 0.05 was considered  
107 significant. Data was analyzed using Stata version 12.

108 The study received an exemption from ethical approval from the Aga Khan University Ethics  
109 Review Committee (ERC reference number: 2020-5178-14123).

## 110 RESULTS

111 A total of 50 cases and 50 controls were included in the analysis after making relevant exclusions  
112 over a period of 4 months from February to June 2020. Median age of cases was 58 years (IQR)  
113 and of controls was 62 years (IQR). The overall male to female ratio was 2.8 and gender  
114 distribution was similar between the groups. The most frequent co-morbidities were diabetes and  
115 hypertension in both groups. The severity of illness was significantly different in both the groups  
116 with a high proportion (80%) of severe/critical COVID-19 patients among cases compared to 30%  
117 in controls ( $p < 0.001$ ). Among those COVID-19 patients with bacterial infections, the majority (72%)  
118 was hospital-acquired and 28% were community-acquired at onset and the commonest site of  
119 infection was hospital-acquired pneumonia (Figure 1). Nine out of 50 had bacteremia. Gram-  
120 negative infections were more common (82%) than gram-positive infections. The most frequently  
121 isolated organism from sputum specimens was multi-drug resistant *Acinetobacter* species in 27%,  
122 followed by multi-drug resistant *Pseudomonas aeruginosa* in 25% (Figure 2). Among patients with  
123 community-acquired infections, the most common organism was *Staphylococcus aureus* (5/14) in  
124 which four were methicillin-resistant and extended spectrum beta lactamase producing (ESBL)  
125 *Klebsiella pneumoniae* in (9/14). Majority of patients had a mono-microbial infection (70%). Seven  
126 out of 50 patients had simultaneous infection at two sites.

127 Among laboratory investigations, the median C-reactive protein and median neutrophil to  
128 lymphocyte ratio were significantly higher in cases compared to controls (Table 1). However, there  
129 was no statistically significant difference between procalcitonin levels in COVID-19 patients with  
130 bacterial infection compared to those without bacterial infection ( $p=0.883$ ). With regard to the  
131 unit of admission, COVID-19 patients with bacterial infections were more frequently admitted to  
132 the Intensive care unit (56%) compared to patients without bacterial infections who were mostly  
133 admitted to the ward (38%) ( $p<0.001$ ). The use of invasive devices such as endotracheal tube and  
134 central venous catheters were also more frequent among cases compared to controls ( $p<0.001$ )  
135 (Table 1). Patients with bacterial infections were managed with invasive ventilation in 56% of  
136 cases compared to 14% controls ( $p<0.001$ ) and with non-invasive ventilation in 64% of cases  
137 compared to 34% controls ( $p=0.003$ ). Comparatively higher proportion of patients who had  
138 bacterial infections had received treatment with systemic steroids (92%) ( $p=0.001$ ). All patients  
139 with bacterial infections had received antibiotics and among controls (32/50) had received  
140 antibiotics. The choice of empiric antibiotics was based on local antibiogram and institutional  
141 guidelines for community acquired pneumonia and definitive antibiotic treatment was decided  
142 based on identification and sensitivity pattern of the isolated organism. The overall mortality was  
143 30%. Patients with COVID-19 having bacterial infections had a comparatively greater proportion of  
144 deaths (42% versus 18%) ( $p=0.009$ ). Out of 21 patients who died, 18 had infection with gram  
145 negative organism with *Acinetobacter* sp ( $n=9$ ) and *Pseudomonas aeruginosa* ( $n=7$ ) being most  
146 common isolates. The median length of stay was also significantly longer among cases compared  
147 to controls (12.5 versus 7.5 days) ( $p=0.001$ ). Multivariable logistic regression showed that patients  
148 who were severe to critically ill at the time of admission with COVID-19 were 4.42 times (95% CI;

149 1.63-11.9) at risk for bacterial infection and treatment with steroids was also a significant risk  
150 factor (AOR: 4.60; 95% CI 1.24-17.05). Admission to ward unit was found to be protective (OR:  
151 0.15; 95% CI 0.02-0.75).

## 152 DISCUSSION

153 Our study found that there is a significant association of severity of illness with COVID-19 at  
154 presentation and treatment with steroids with the development of superimposed bacterial  
155 infection. Our patient cohort had moderate to severe or critical COVID-19 at the time of  
156 hospitalization and we had excluded patients who had specimen positive with contaminants or  
157 who were presumed to be colonized and without clinically significant infection. There was a high  
158 male to the female ratio and several studies have reported a greater risk of severe illness with  
159 COVID-19 in males compared to females [11, 12]. We had very few community-acquired infections  
160 and the majority were hospital-acquired. This is similar to study conducted by Hughes et al. from  
161 UK where only 3.2% co-infections were reported [13] and a study from Spain describing the  
162 incidence of co-infections [14]. This was also confirmed in a meta-analysis where the reported  
163 prevalence of co-infections was 3.5% [15]. Majority of the patients in our cohort developed  
164 hospital acquired infections. This is consistent with other reported literature [15, 16]. The most  
165 common site of infection was pneumonia and this is in concordance with initial reports from China  
166 [16]. Gram-negative infections have dominated as far as the type of organisms is concerned and  
167 this is similarly seen in studies reported from other parts of the world describing superinfections  
168 or secondary bacterial infections [14, 16]. There is a lack of reported literature on the sensitivity  
169 patterns of organisms isolated. In our study, we found multi-drug resistant Acinetobacter as the  
170 predominant pathogen causing hospital acquired infections and methicillin resistant



171 *Staphylococcus aureus* as the main cause of co-infection in COVID-19 in our patients. A case series  
172 of 19 patients from Iran has described *Acinetobacter baumannii* in majority of patients requiring  
173 ICU admission[17] which reflects epidemiological similarity to Pakistan. In our study, the overall  
174 mortality was 30% and was higher in those who had bacterial infections. This is also consistent  
175 with data reported from Europe and parts of Asia [15, 18]. Moreover, we found that overall  
176 antibiotic utilization was 82% and was 64% in patients who had no evidence of bacterial infection.  
177 This has also been similarly reported [18] indicating widespread injudicious use of antibiotics  
178 which can potentiate the problem of antimicrobial resistance. In our study, we did not find  
179 procalcitonin to be a reliable marker of distinguishing patients who had bacterial infections and  
180 those who did not have bacterial infections. Although studies have described procalcitonin levels  
181 to remain normal in severe COVID-19, whether they increase in bacterial infections has not been  
182 reported and indicates need of large comparative studies exploring this relationship[19]. Our  
183 study is the first comparative study with regard to bacterial infections in the setting of moderate  
184 and severe to critical COVID-19 and describes the sensitivity pattern of organisms in addition to  
185 clearly classifying them into community and hospital acquired infections.

## 186 Conclusions

187 Our study highlights need for improving antibiotic stewardship practices and reserving antibiotics  
188 for those who are severely ill with COVID-19 at presentation and require treatment with systemic  
189 steroids and provides insight into the lack of utility of serum procalcitonin as a marker of bacterial  
190 sepsis in this setting.

191 **LIMITATIONS**

192 Our study is limited as it's a single center experience which might affect generalizability.

193 Moreover, we did not have molecular methods and genotyping available for our bacterial isolates

194 and information on the isolation rate of the prevalent Gram negatives and MRSA in non-COVID-19

195 patients over the study period was not available to draw comparisons with rates of infection seen

196 in COVID-19 patients.

197

198 **List of Abbreviations:**

IQR	Interquartile range
ERC	Ethics review committee
ESBL	Extended-spectrum Beta -lactamase
C-RP	C-reactive protein
COVID-19	Coronavirus infection disease-19
MDR	Multi-drug resistant
MRSA	Methicillin-resistant Staphylococcus aureus

199 **DECLARATIONS**

200 **Ethics approval and consent to participate**

201 The study was submitted for ethical approval to the Aga Khan University Ethics review committee  
202 and received exemption (ERC reference number: 2020-5178-14123). Consent to participate was  
203 not required because there was no direct interaction with participants. The study was eligible for  
204 exemption as data was collected from records and no personal identifiers were recorded or used.

205 **Consent for publication**

206 Not applicable

207 **Availability of data and materials**

208 All data generated or analysed during this study are included in this published article

209 **Competing interests**

210 The authors declare that they have no competing interests

211 **Funding**

212 No funding was obtained for this study.

213 **Authors' contributions**

214 NN conceived idea, major contributor to manuscript, collected and analyzed data

215 FR conceived idea, contributed to manuscript, collected data

216 FU collected data and contributor to manuscript

217 All authors read and approved the manuscript

218 **Acknowledgements**

219 Not applicable

## 220 REFERENCES

- 221 1. Taubenberger JK, Morens DM. The 1918 influenza pandemic and its legacy. Cold Spring Harbor  
222 perspectives in medicine. 2020;10(10):a038695.
- 223 2. Rice TW, Rubinson L, Uyeki TM, Vaughn FL, John BB, Miller III RR, et al. Critical illness from 2009  
224 pandemic influenza A (H1N1) virus and bacterial co-infection in the United States. Critical care medicine.  
225 2012;40(5):1487.
- 226 3. Clancy CJ, Nguyen MH. COVID-19, superinfections and antimicrobial development: What can we  
227 expect? Clinical Infectious Diseases. 2020.
- 228 4. Lehmann CJ, Pho MT, Pitrak D, Ridgway JP, Pettit NN. Community acquired co-infection in COVID-  
229 19: a retrospective observational experience. Clinical Infectious Diseases. 2020.
- 230 5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult  
231 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet. 2020.
- 232 6. Rawson TM, Moore LS, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and  
233 fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial  
234 prescribing. Clinical Infectious Diseases. 2020.
- 235 7. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review  
236 and meta-analysis. Journal of Infection. 2020.
- 237 8. Vaughn VM, Gandhi T, Petty LA, Patel PK, Prescott HC, Malani AN, et al. Empiric antibacterial  
238 therapy and community-onset bacterial co-infection in patients hospitalized with COVID-19: a multi-  
239 hospital cohort study. Clinical Infectious Diseases. 2020.
- 240 9. Organization WH. Clinical management of COVID-19: interim guidance, 27 May 2020. World Health  
241 Organization; 2020.
- 242 10. Control CfD. CDC/NHSN Surveillance Definitions for Specific Types of Infections 2020 [Available  
243 from: [https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef\\_current.pdf](https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf).
- 244 11. Stall NM, Wu W, Lapointe-Shaw L, Fisman DN, Giannakeas V, Hillmer MP, et al. Sex- and Age-  
245 Specific Differences in COVID-19 Testing, Cases, and Outcomes: A Population-Wide Study in Ontario,  
246 Canada. J Am Geriatr Soc. 2020;68(10):2188-91.
- 247 12. Alkhouli M, Nanjundappa A, Annie F, Bates MC, Bhatt DL. Sex Differences in Case Fatality Rate of  
248 COVID-19: Insights From a Multinational Registry. Mayo Clin Proc. 2020;95(8):1613-20.
- 249 13. Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection among  
250 hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clinical  
251 Microbiology and Infection. 2020;26(10):1395-9.
- 252 14. Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et al.  
253 Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective  
254 cohort study. Clinical Microbiology and Infection.
- 255 15. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-  
256 infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis.  
257 Clinical Microbiology and Infection. 2020.
- 258 16. He Y, Li W, Wang Z, Chen H, Tian L, Liu D. Nosocomial infection among patients with COVID-19: A  
259 retrospective data analysis of 918 cases from a single center in Wuhan, China. Infection control and  
260 hospital epidemiology. 2020;41(8):982-3.
- 261 17. Sharifipour E, Shams S, Esmkhani M, Khodadadi J, Fotouhi-Ardakani R, Koohpaei A, et al. Evaluation  
262 of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU. BMC Infectious  
263 Diseases. 2020;20(1):646.
- 264 18. Goncalves Mendes Neto A, Lo KB, Wattoo A, Salacup G, Pelayo J, DeJoy III R, et al. Bacterial  
265 infections and patterns of antibiotic use in patients with COVID-19. Journal of Medical Virology.n/a(n/a).

266 19. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A  
267 meta-analysis. Clinica chimica acta; international journal of clinical chemistry. 2020;505:190-1.

268

269

270 Table 1: Comparison of moderate and severe COVID-19 patients with and without bacterial  
 271 infections

<b>Variables</b>	<b>All (N=100)</b>	<b>COVID-19 with bacterial infection (n=50)</b>	<b>COVID-19 without bacterial infection (n=50)</b>	<b>p- value</b>
<b>Median age in years (IQR)</b>	60 (52-70)	58 (49-67)	62 (54-70)	0.512
<b>Sex</b>				
<b>Male</b>	74 (74%)	39 (78%)	35 (70%)	0.362
<b>Female</b>	26 (26%)	11 (22%)	15 (30%)	
<b>Co-morbids</b>				
<b>Diabetes</b>	56 (56%)	27 (54%)	29 (58%)	0.687
<b>Hypertension</b>	55 (55%)	25 (50%)	30 (60%)	0.315
<b>Ischemic heart disease</b>	28 (28%)	13 (26%)	15 (30%)	0.656
<b>Chronic kidney disease</b>	17 (17%)	9 (18%)	8 (16%)	0.79
<b>COPD</b>	3 (3%)	2 (4%)	1 (2%)	
<b>Severity of illness</b>				<b>&lt;0.001</b>
<b>Moderate</b>	43 (43%)	10 (20%)	33 (66%)	
<b>Severe</b>	57 (57%)	40 (80%)	17 (34%)	

---

**Laboratory Investigations**

<b>Median C-Reactive Protein mg/L (IQR)</b>	147.47 (48.5 – 199.64)	169.34 (95.86- 231.19)	81.57 (34.36- 197.19)	0.009
<b>Median Neutrophil to lymphocyte ratio (IQR)</b>	6.20 (3.29-11.12)	8.58 (5.41-14.66)	4.28 (2.96-7.89)	0.001
<b>Median Procalcitonin ng/ml (IQR)</b>	0.25 (0.107-0.6)	0.369 (0.15-1.78)	0.14 (0.07-0.44)	0.883

---

**Type of Ward**

<b>ICU Admission</b>	37 (37%)	28 (56%)	9 (18%)	<0.001
<b>SCU Admission</b>	42 (42%)	20 (40%)	22 (44%)	0.685
<b>Ward admission</b>	21 (21%)	2 (4%)	19 (38%)	<0.001

---

**Presence of invasive devices**

<b>Endotracheal tube</b>	37 (37%)	28 (56%)	7 (14%)	<0.001
<b>CVP</b>	39 (39%)	29 (58%)	10 (20%)	<0.001

---

**Treatment**

<b>Invasive ventilation</b>	35 (35%)	28 (56%)	7 (14%)	<0.001
<b>Non-invasive ventilation</b>	49 (49)	32 (64%)	17 (34%)	0.003
<b>Antibiotics</b>	82 (82%)	50 (100%)	32 (64%)	<0.001

---




<b>Tocilizumab</b>	29 (29%)	18 (36%)	11 (22%)	0.123
<b>Systemic steroids</b>	77 (77%)	46 (92%)	31 (62%)	0.001
<b>Outcomes</b>				
<b>Length of stay [median (IQR) days]</b>	9 (6-14)	12.5 (7-18)	7.5 (4-11)	0.001
<b>Dead</b>	30 (30%)	21 (42%)	9 (18%)	0.009
<b>Discharged</b>	70 (70%)	29 (58%)	41 (82%)	

272

273

274 Figure 1: Sites of Infection in moderate and severe COVID-19 patients with bacterial infections

275




276

277

278 Figure 2: Clinically significant isolates from culture specimens in patients with moderate and  
279 severe COVID-19

280

281



282